The bill would amend the Public Health Service Act to insert a new section (1712) that requires the Secretary of Health and Human Services to establish drug adherence guidelines with a goal of achieving 90 percent adherence for all Medicare Part B and D drugs. In developing these guidelines, the Secretary must incorporate artificial intelligence and machine learning technologies and, to the maximum extent practicable, promote the use of generic and biosimilar drugs.
The definitions for Medicare Part B drugs and Medicare Part D drugs are included to clarify scope.
At a Glance
What It Does
Directs the Secretary to establish drug adherence guidelines with a 90 percent adherence target for Medicare Part B and Part D drugs.
Who It Affects
Directly affects Medicare beneficiaries who use Part B or Part D drugs, prescribers, pharmacists, Part D sponsors, and CMS administering the program.
Why It Matters
Sets a national standard for adherence monitoring and ties it to technology use and generic/biosimilar utilization, signaling a shift in how adherence is measured and incentivized.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill proposes a formal change to the Public Health Service Act by inserting a new section (1712) that creates an obligation for the Secretary of Health and Human Services to establish guidelines aimed at achieving a 90 percent adherence rate for Medicare Part B and Part D drugs. These guidelines would guide how adherence is defined, measured, and supported by federal programs.
A key feature is the requirement to incorporate artificial intelligence and machine learning tools, suggesting an emphasis on data-driven tracking and decision support to improve adherence. The bill also directs that, whenever possible, the guidelines should promote the use of generic and biosimilar drugs to reduce costs and expand access to therapies.
It provides definitional clarity by defining what constitutes Medicare Part B and Part D drugs in this context. While the text outlines the policy objectives and mechanisms, it does not spell out enforcement or penalties within the excerpt provided and leaves operational specifics to be developed by HHS.
The overall aim is a more data-informed approach to ensuring patients take prescribed therapies, with a stronger role for technology and generic drug options in driving adherence.
The Five Things You Need to Know
The bill requires the Secretary to establish adherence guidelines with a 90% target for Part B and Part D drugs.
Guidelines must incorporate AI and ML technologies.
The new provision inserts Section 1712 into Title XVII of the Public Health Service Act.
Definitions for Medicare Part B and Part D drugs are included in the new section.
Enforcement details are not specified in the text provided.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
General directive: establish drug adherence guidelines
This subsection creates the core obligation for the Secretary to establish guidelines governing drug adherence, with the explicit objective of achieving 90 percent adherence for Medicare Part B and Part D drugs. It frames adherence as a federally guided standard to be implemented across applicable drug programs and payment mechanisms.
Contents of the guidelines: AI/ML and generics
This subsection specifies what the guidelines must contain: an incorporation of artificial intelligence and machine learning technologies to monitor, measure, and support adherence, and, to the maximum extent practicable, a promotion of generic and biosimilar drugs to improve access and lower costs. It signals a technology-forward and cost-conscious approach to adherence strategy.
Definitions: Part B and Part D drugs
This subsection provides the definitions for what constitutes a Medicare Part B drug and a Medicare Part D drug within the new adherence framework, ensuring clear scope for the guidelines and avoiding ambiguity in later application.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Medicare beneficiaries prescribed Part B drugs who may experience more consistent therapy outcomes through higher adherence.
- Prescribers and pharmacists who can leverage AI-enabled adherence tools to support patients and optimize prescribing decisions.
- Medicare Part D plan sponsors and other payers seeking standardized adherence measurement and potentially reduced waste or wasteful spending through better adherence.
- Manufacturers of generics and biosimilars may benefit from greater utilization and competition, potentially lowering drug costs.
- CMS and other HHS programs gain a clearer, data-driven framework for program oversight and performance measurement.
Who Bears the Cost
- HHS/CMS incurs administrative costs to develop, implement, and monitor the adherence guidelines.
- Health plans and Part D sponsors may face increased compliance and IT integration costs to track adherence and report metrics.
- Healthcare providers and clinics may need to adapt workflows and invest in AI-enabled tools or training to support adherence efforts.
- Pharmaceutical manufacturers of non-generics could experience market pressure and pricing dynamics as generics/biosimilars are promoted.
- IT vendors and AI providers may see demand for adherence-monitoring technologies and related services.
Key Issues
The Core Tension
Balancing an ambitious 90% adherence target and the use of advanced AI tools against patient autonomy, clinical nuance, and privacy concerns is the central dilemma. The bill aims for higher adherence and cost containment through generics while transferring significant implementation responsibility to HHS and digital health stakeholders, creating potential conflicts between standardization and individualized care.
The bill creates a significant shift toward data-driven adherence management, leveraging AI/ML and a preference for generics/biosimilars. This raises questions about data privacy, the reliability and bias of AI tools, and how adherence will be measured in diverse patient populations.
The lack of explicit enforcement or penalty structures in the excerpt means implementation guidance—such as metrics, reporting requirements, and timelines—will likely depend on future rulemaking by HHS. Additionally, anchoring adherence to a numerical target (90%) could create pressure on prescribers and health plans to demonstrate compliance, potentially impacting clinical decision-making and drug access if not carefully designed.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.